Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Apnimed banks $351.8m as FDA clock runs down on first-in-class sleep apnoea pill

The US drugmaker says its cash should last into the second quarter of 2028, well past an agency decision on its once-nightly combination therapy due by 28 February 2027.

16 Nov 2026 · Apnimed, Inc. APMD · Company news

Apnimed has told investors it has enough money to operate beyond the point at which the US Food and Drug Administration is due to rule on its obstructive sleep apnoea candidate. The company reported cash of $351.8m in its third-quarter update on 16 November 2026 and said that sum should fund operations into the second quarter of 2028.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Apnimed, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →